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Introduction 
Abrupt withdrawal from benzodiazepines (BZs) produces anxiety 
and potently activates the hypothalamic-pituitary-adrenal (HPA) 
axis in animals (Eisenberg 1987; Owens et al 1991). Alcohol 
withdrawal similarly activates the HPA axis in humans (Adinoff et 
al 1991; yon Bardeleben et al 1989). The human HPA response to 
BZ withdrawal has been little studied (Adam et al 1984), but the 
animal and human alcohol data predict activation. 
Abrupt BZ withdrawal also produces increases in hippocampal 
and cortical cholecystokinin (CCK) receptor number (Harro et al 
1990) and in pre-proCCK mRNA (Rattray et al 1993). CCK agon- 
ists can induce anxiety and activate hippocampal neurons; both of 
these effects are antagonized by BZs (Bradwejn and de Montigny 
1984; de Montigny 1989). CCK also activates the HPA axis (Abel- 
son et al 1991), whereas BZs inhibit it (Owens et al 1991). CCK 
and BZs thus appear to interact antagonistically in modulating 
anxiety and the stress axis, raising the possibility that BZ with- 
drawal-induced anxiety and HPA axis activation could be me- 
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diated by CCK. If so, then a CCK receptor antagonist may be able 
to block the anxiety and HPA axis activation produced by BZ 
withdrawal. A selective CCK-B receptor antagonist (CI-988) has 
in fact been shown to block BZ withdrawal anxiety in animal 
models (Costall et al 1991; Singh et al 1992). 
We explored the HPA responses to BZ withdrawal in humans 
and the effects of a CCK antagonist (CI-988) on this response and 
on withdrawal symptoms by using overnight withdrawal from 
alprazolam. Chronic alprazolam users frequently experience with- 
drawal symptoms upon missing a single dose, so we could study 
the early stages of withdrawal by postponing their usual morning 
dose. Because of safety concerns in testing a new class of medica- 
tion in a new paradigm, we chose a low dose of CI-988 for this 
preliminary study and were particularly interested in neuroendo- 
crine effects. 
Methods 
Six patients under long-term treatment with alprazolarn for panic 
disorder were studied after informed consent was obtained. Each 
subject was studied three times, separated by 1 week, under the 
following conditions 1) nonwithdrawal (usual morning dose of 
alprazolam given), 2) untreated withdrawal (AM alprazolam post- 
poned, placebos given), and 3) treated withdrawal (AM alprazolam 
postponed, 25 mg ofCI-988 given). Because full randomization of 
order with three conditions requires a larger sample than was 
feasible for this pilot study and because we wished to directly 
compare CI-988 to placebo, these latter two conditions were 
presented in a double-blind, cross-over design with constrained 
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random assignment to order so each order was equally repre- 
sented. The nonwithdrawal condition was always given first and 
primarily provided control data for neuroendocrine analyses. 
Presenting the nonwithdrawal condition first prevented subject 
attrition by avoiding a stressful withdrawal experience upon first 
exposure to the laboratory. It also ensured that predictable order 
effects (increased anxiety and HPA activation during first expo- 
sure to the laboratory; Abelson et al 1994), would not confound 
hypothesis confirmation, in that alprazolam would have to over- 
come these novelty effects to confirm our prediction that nonwith- 
drawal would be less activating than withdrawal. 
All subjects were medically healthy, nondepressed (Ham-D 
<18), free of other psychotropic medication or drugs of abuse 
(confirmed by urine drug screen), and of non-child-bearing poten- 
tial. Their mean age was 43.2 yr (range: 30--60). Diagnoses were 
confirmed by a structured clinical interview (SCID). All had a 
primary diagnosis of panic disorder, but five had additional SCID 
diagnoses. Two subjects had simple phobias (heights, elevators). 
One of these also had generalized anxiety disorder (GAD). Two 
subjects had histories of substance abuse (alcohol, substance free 
for 2 years; marijuana, substance free for 10 years). One of these 
(the former alcohol abuser) also had obsessive-compulsive dis- 
order. One subject had social phobia, GAD, and a history of a 
major depressive episode. Entry criteria required at least 6 months 
on at least 3 times/day dosing of a BZ equivalent to at least 3 
mg/day of alprazolam, and subjective report of withdrawal symp- 
toms within 12 hours after a dose (anxiety symptoms upon missing 
a dose or on arising after a night of sleep). Subjects had been on 
BZs for a mean of 5.6 yr (range: 8 too-10 yr); all but one had taken 
alprazolam daily for more than 4 years. The only exception had 
been on alprazolam daily for 2 months after 6 months on daily 
clorazepate. Mean dose at time of study was 4 mg/day (range: 
3--6). 
All patients underwent a trial withdrawal at home 1 week prior to 
study. They held their morning dose until they had gone without 
drug for 8-16 hours, with hourly telephone monitoring of with- 
drawal symptoms by the study psychiatrist (JLA). The approximate 
time of onset of withdrawal symptoms was determined for each 
patient, and alprazolam was resumed before symptoms became 
severe. Patients reported to a Clinical Research Center (CRC) on 
the evening prior to study, where they received a last dose of 
alprazolarn at a time determined by their preadmission trial to be 
likely to produce mild symptoms of withdrawal by 8 AM the next 
day. They remained in the CRC overnight, with minimal activity 
and fasting from 11 PM until noon the next day. Intravenous access 
was established by 7:00 AM. Blood samples were obtained at 7:30, 
7:45, 8:00 AM, and every 30 rain thereafter until noon. Symptoms 
and vital signs were monitored hourly. Heart rate (HR), systolic 
blood pressure (SBP), and diastolic blood pressure (DBP) were 
measured using an Air-Shields automated monitor. Anxiety was 
measured using a visual analogue scale (VAS), and withdrawal 
symptoms were monitored with a revised form of the Liebowitz 
Withdrawal Symptom Checklist (WDS) (Noyes etal 1991). 
Alprazolam or alprazolam placebo were administered single- 
blindly at 7:00 AM. CI-988 or CI-988 placebo were administered at 
8:00 AM. On the first visit to the CRC, all subjects received their 
regular alprazolam dose at 7:00 AM and a placebo at 8:00 AM 
(nonwithdrawal condition). On their second and third visits they 
received placebo at 7:00 AM and were in early withdrawal when 
they received double-blind administration of CI-988 or placebo at 
8:00 AM. All patients resumed their usual alprazolam dosing at 
noon .  
Adrenocorticotropic hormone (ACTH) was measured by radio- 
immunoassay, with a sensitivity of 6 pg/ml and intraassay and 
interassay coefficients of variation (CVs) of less than 10%. Corti- 
sol was measured by high-performance liquid chromatography, 
with a sensitivity of 0.1 i~g/dl and CVs of <6%. 
Areas under the curve (AUC, by trapezoidal approximation) for 
ACTH and cortisol levels from 9:00 AM until noon were used as 
the measures of HPA axis activity for hypothesis testing. These 
provide the best estimate of overall axis activity during a time 
period that allows for the onset of action ofCI-988 and alprazolam 
and captures the fullest degree of withdrawal to which we sub- 
jected the subjects. Symptom measures for hypothesis testing were 
the peak VAS anxiety rating and the peak total WDS score be- 
tween 9:00 AM and noon. Peak scores were used to capture maxi- 
mum symptom development from symptom response curves with 
considerable intersubject variability in time course. The following 
four predictions were tested: 1) Symptoms will be greater during 
untreated withdrawal than on the nonwithdrawal day (placebo vs. 
alprazolam); 2) ACTH and cortisol secretion will be greater during 
untreated withdrawal than on the nonwithdrawal day; 3) symp- 
toms will be less during treated withdrawal than during untreated 
withdrawal (CI-988 vs. placebo); and 4) ACTH and cortisol secre- 
tion will be less during treated withdrawal than during untreated 
withdrawal. All hypotheses make directional prediction, and hy- 
pothesis testing comparisons were planned prior to data collection, 
so we used one-tailed, paired t tests with .05 level of significance. 
Results 
Means, standard deviations, and t test results are presented in 
Table 1. Hypotheses 1, 2, and 4 were supported. Alprazolam with- 
drawal (holding the usual morning dose in chronically treated 
patients) produced significant anxiety and withdrawal symptoms 
and activated the HPA axis. CI-988 successfully attenuated the 
cortisol response to alprazolam withdrawal. The ACTH response 
was also reduced, though not significantly. Hypothesis 3 was not 
supported. Following CI-988 administration, withdrawal symp- 
toms were not reduced but were nonsignificantly elevated. 
To follow up the significant effects of withdrawal and CI-988 
treatment on cortisol secretion, a full set of paired t tests was 
conducted, comparing all pairings of nonwithdrawal, untreated 
withdrawal, and treated withdrawal at every time point. The com- 
plete cortisol response curve and results of these additional com- 
parisons are presented in Figure 1. There were no differences 
between conditions at baseline. The alprazolam (nonwithdrawal) 
and CI-988 conditions did not differ significantly from each other 
at any time point. Both treated conditions differed from untreated 
withdrawal at the majority of time points between 9:00 AM and 
noon, when withdrawal effects were expected to be most evident. 
To verify that there were no baseline differences between condi- 
tions, we conducted single-factor analyses of variance (ANOVAs) 
on baseline ACTH and cortisol levels (mean of the 7:30, 7:45, and 
8:00 AM measures) and baseline symptom ratings (7:30 AM 
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Table 1. Mean(___ SD) Symptom and Hormone Levels in Three Treatment Conditions, With Statistical 
Comparisons (Paired t Tests) 
Untreated Treated Alprazolarn CI-988 
Nonwithdrawal withdrawal withdrawal vs. vs. 
(Alprazolam) (Placebo) (CI-988) placebo placebo 
VAS anxiety (peak) 35.0 _-. 16.3 55.2 "!-_ 30.8 65.8 +_ 32.3 
WDS total (peak) 3.2 _-_ 2.6 9.7 _ 7.6 13.2 -+ 9.5 
ACTH (AUC) 3597.5 - 1350.6 5100 "L-_ 2510.6 4500 __. 2470.8 
Cortisol (AUC) 1775 _+ 373.2 2393 _ 501.8 1971 +_ 396.4 
t = 2.6,p =.025 t=0.6,p =.55 
t=2.9,p=.O18 t= 1.0,p =.37 
t=2.5,p =.026 t=0.9,p=.21 
t =4.4,p = .003 t = 6.6,p = .0006 
VAS = visual analogue scale; WDS = Liebowitz Withdrawal Symptom Checklist; ACTH = adrenocorticotropic hormone; 
AUC = area under the curve. 
VAS/anxiety and WDS total). There were no significant differ- 
ences among the three treatment conditions in these analyses. 
To determine whether patients found the experimental situation 
less stressful as they gained more experience with it, we compared 
HPA and symptom responses on visits 2 and 3, since during both of 
these visits patients were put into alprazolam withdrawal. Patients 
experienced significantly fewer symptoms of anxiety and with- 
drawal the second time they were withdrawn (t = 3.5, p = .02 for 
VAS anxiety; t = 2.5, p = .05 for WDS total score). ACTH and 
cortisol did not differ between visits (t < 0.6, p > .50 for both). 
Multiple analyses could detect no significant effect ofCI-988 on 
HR or BP. Data from CI-988 and placebo days were combined and 
compared to alprazolam day data to search for cardiovascular 
effects of withdrawal. The only detectable trend was for elevated 
SBP during "late" withdrawal (11:00 AM to noon) compared to the 
same time period on nonwithdrawal day (t = 2.1, p = 0.09). 
Discussion 
These data must be considered preliminary because of the small 
sample and use of only a single, low dose of CI-988. Generaliza- 
tion to a nonpatient population may also not be appropriate, since 
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Figure 1. Cortisol responses in chronic alprazolam users to un- 
treated overnight withdrawal (placebo), withdrawal treated with 
CI988, and nonwithdrawal (alprazolam). Alprazolandplacebo was 
given at 0700; CI988/placebo was given at 0800. Untreated with- 
drawal produced significantly (p < .05) elevated cortisol levels 
relative to alprazolam at points marked with asterisks (*). Un- 
treated withdrawal produced significantly elevated cortisol levels 
relative to CI988 at points marked with daggers (t). Alprazolam 
and CI988 treatments did not differ significantly from each other at 
any time points. 
patients with panic disorder may have altered sensitivities to with- 
drawal anxiety, HPA axis activation, and CCK or BZ receptor 
stimulation. With these caveats in mind, however, the data do 
support the hypothesis that BZ withdrawal activates the HPA axis. 
Normal diurnal variation should produce falling ACTH and corti- 
sol levels during the morning hours. When chronic users of alpra- 
zolam were denied their usual morning dose of this short-acting 
BZ, their ACTH and cortisol levels did not follow this normal 
pattern but instead remained level throughout the morning. When 
their morning alprazolam was administered, levels did fall and 
were significantly lower than in the "withdrawn" state. The mag- 
nitude of the withdrawal effect was likely greatly underestimated 
in this study, since HPA axis activity was probably elevated on the 
nonwithdrawal day by a first-visit "novelty" effect (Abelson et al 
1994) and since, for ethical reasons, we were unwilling to hold 
alprazolam for more than 16 hours. The appearance of cardiovas- 
cular effects (SBP) late in our withdrawal period (11:00 AM to 
noon) suggests that, though our subjects were already experienc- 
ing withdrawal symptoms at 8:00 AM, they may have been just 
beginning to enter a more active state of physiological withdrawal 
when we terminated our observation period at noon. 
An alternative interpretation of the data is available, in that 
lower cortisol levels in the nonwithdrawal condition could reflect 
alprazolam's ability to acutely depress HPA activity rather than 
the ability of withdrawal to elevate it. Though acute administration 
of BZs has been shown to decrease ACTH and cortisol levels, the 
literature is not entirely consistent (Schuckit et al 1992), and the 
effects of acute administration after long-term, daily administra- 
tion have not been studied. Separate data from our laboratory 
(unpublished) indicate that panic patients on alprazolam do not 
differ from untreated normal controls in their decline in cortisol 
over the morning hours and support our conclusion that the differ- 
ences between withdrawal and nonwithdrawal in the current data 
set are due to the failure of withdrawing patients to show the 
normal diurnal decline. 
Administration of the CCK-B antagonist CI-988 successfully 
attenuated withdrawal-induced HPA axis activation in this study, 
even though it failed to reduce withdrawal anxiety. This finding 
strongly supports our hypothesis, based on work with a CCK-B 
agonist (Abelson et al 1991), that CCK plays a physiological role 
in regulating the HPA axis and does so independently of its effects 
on anxiety and subjective distress. CI-988 was able to reduce 
cortisol levels, compared to placebo, even though withdrawal 
symptoms and anxiety levels were nonsignificantly higher in the 
CI-988 condition. Its success in inhibiting the HPA axis is particu- 
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larly impressive in light of the relatively low dose chosen for this 
pilot study and its pharmacokinetics (Tm~ of 2-3 hours), which 
should have produced maximal effects during only a part of the 
period studied. That the HPA effect is more readily seen for corti- 
sol than for ACTH may be because cortisol provides a more reli- 
able indicator of stress axis activity when samples are obtained 
only every 30 minutes. More frequent sampling is needed to fully 
capture ACTH secretory episodes, since these are pulsatile and the 
ACTH half-life is quite short. It is also possible that CI-988 has 
some direct effect at the adrenal level. Our data are consistent with 
the BZ literature, which has more readily demonstrated effects of 
BZs on cortisol levels than ACTH levels (Schuckit et al 1992). 
Though CI-988 appeared to suppress cortisol to nearly the same 
extent as alprazolam, these data must be interpreted with great 
caution. The study was not designed to directly compare the two 
drugs, but rather to test specific hypotheses by comparing both to 
placebo. Order effects are not controlled in an alprazolam-CI-988 
comparison, in that alprazolam was always given first. Novelty 
effects may have made CI-988 look better relative to alprazolam by 
exaggerating symptom levels and I-IPA activity in the alprazolam 
condition. Differing pharmacokinetics, however, worked to the ad- 
vantage of alprazolam in that its earlier administration and quicker 
onset of action should have led to greater pharmacological activity 
over the period studied. Further work with other designs is needed. 
Our anxiety and withdrawal symptom data must also be inter- 
preted cautiously. Because of the low dose of CI-988 used and the 
combination of a small sample and the strong confounding effect 
of order on symptom responses to withdrawal, the data can shed no 
real light on the effect of CI-988 on withdrawal anxiety. Follow-up 
studies using larger samples and parallel group designs are 
planned. Our demonstration of CI-988' s ability to reduce "stress"- 
induced cortisol release is extremely encouraging, since in early 
animal studies of other agents this ability consistently predicted 
anxiolytic efficacy (Lahti and Barsuhn 1974). 
Finally, we want to call attention to the striking effect of having 
"been through it once" in reducing the anxiety and symptom 
response to the withdrawal experience. Both subjective observa- 
tion and the data analyses readily demonstrated that the second 
experience with withdrawal was far less distressing than the first. 
Whether this effect reflects panic patients' hypersensitivity to 
"novelty" (in this case the experience of withdrawal symptoms in 
a novel research environment) or the rapidity and power of desen- 
sitization in these patients, we believe that it may reflect a critical 
underlying feature of panic disorder. It deserves more extensive 
exploration in its own right and must be considered in all studies of 
panic that expose patients to novel experiences and environments. 
This research was supported in part by Clinical Research Center Grant 
#M01RR00042 and by a grant from Parke-Davis. 
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